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Available online 7 April 2016Introduction: Cardiac phenotypes should be pronounced in hereditary hemorrhagic telangiectasia (HHT) due to
frequent systemic arteriovenous malformations (AVMs), iron deﬁciency anemia, hypoxemia, hyperdynamic cir-
culations, venous thromboemboli, and paradoxical emboli through pulmonary AVMs.
Methods/results: In an international survey, 1025 respondents (median age 55 years)met HHT diagnostic criteria:
942 (91.9%) reported nosebleeds, 452 (44.1%) at least daily. AVMswere commonly reported in pulmonary (544,
53%), hepatic (194, 18.9%) and/or cerebral (92, 9.0%) circulations. 770/1025 (75%) had used iron tablets, 256
(25.0%) intravenous iron, and 374 (36.5%) received blood transfusions. Arrhythmias were reported by 113/
1025 (11%, including 44 (4.3%) with atrial ﬁbrillation), angina by 36 (3.5%), and cardiac failure by 26 (2.5%). In
multivariate logistic regression, these phenotypes were associated with hepatic AVMs/pulmonary hypertension
(relatively interchangeable variables), blood transfusions, and intravenous iron. Cardiac insufﬁciency/failure
often provokes intensive anemia treatments, but associationswith arrhythmias, particularlywith a greater trans-
fusion burden, were less easy to explain.
Myocardial infarction (23/1025; 2.2%), and abnormal coronary angiogram (≤31/76, ≤54%) rates appeared low.
Provocative preliminary data were obtained including HHT-affected respondents' parents and grandparents in
whom HHT could be conﬁdently assigned, or excluded based on autosomal dominant inheritance patterns: in
crude and survival analyses, myocardial infarctions were reported less frequently for individuals with HHT, par-
ticularly for males (p = 0.001).
Conclusion:Arrhythmias are themost common cardiac phenotype inHHT, and likely to be aggravated by iron de-
ﬁciency anemia, its treatments, and/or high output states due to AVMs. Myocardial infarction rates may be re-
duced in this apparently high risk population.
© 2016 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-ND li-
cense (http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Cardiac phenotypes should be pronounced in individuals with the
inherited vascular disorder, hereditary hemorrhagic telangiectasia
(HHT) which is caused by mutations in the endoglin, ACVRL1 or
SMAD4 genes that encode proteins involved in TGF-beta superfamily
signaling [1,2].
HHT results in systemic and pulmonary arteriovenousmalformations
(AVMs), and iron deﬁciency anemia, usually attributable to recurrent
nosebleeds. As discussed recently [3], signiﬁcant systemic arteriovenous
malformations (AVMs) reduce systemic vascular resistance: supra-
normal cardiac outputs are required to maintain arterial blood pressure
[4] with hemodynamic indices improving if hepatic AVMs are treated
by liver transplantation [5]. Bleeding from nasal and gastrointestinal tel-
angiectasia leads to iron losses of such magnitude that diet is usually in-
sufﬁcient to meet the ‘hemorrhage adjusted iron requirement’ [6].
Resultant iron deﬁciency restricts erythropoiesis, leading to anemia and
increased cardiac output [7,8]. Pulmonary AVMs [9] result in hypoxemia
which increases the cardiac output [9,10,11], and also place patients at
risk of paradoxical emboli proposed to cause angina or myocardial in-
farction in patients with normal coronary arteries [12]. Paradoxical em-
bolic stroke risks are greater in iron deﬁcient HHT/pulmonary AVM
patients [13] who, as in the general population, can display exuberant
platelet aggregation to serotonin (5HT) [13]. Additionally, HHT patients
are more prone to venous thromboemboli (VTE) than the general popu-
lation [14], apparently exacerbated by iron deﬁciency, and elevated co-
agulation factor VIII [14] which is an established risk factor for ﬁrst and
recurrent VTE in the general population [15–19].
Despite these additional circulatory demands and stresses, received
wisdom in the HHT ﬁeld is that speciﬁc cardiac events may be relatively
rare. Undoubtedly high output cardiac failure is a feared complication of
hepatic AVMs [20], and arrhythmias can be a presenting feature of pul-
monary AVMs [21]. However, a survey published in abstract format in
1997 suggested reduced rates of angina [22].
Furthermore, it is known that despite early deaths [23–25] due to
HHT-related phenotypes such as cerebral hemorrhage [26–28], cere-
bral abscess [29,30], or maternal death during pregnancy [31], life
expectancy is remarkably well preserved and approaches normal in
the latest series from Denmark [23,32,33], though this has not been
seen in all countries [24,25]. Cancer protection has been identiﬁed
as one potential mechanism for the good life expectancy [34].We hy-
pothesized that reduced rates of life-limiting cardiovascular diseases
may be another.
Here, we report results from a systematic unbiased survey that was
designed to evaluate cardiac phenotypes in patients with HHT.
2. Methods
2.1. Study design
To capture cardiac histories in an unbiased manner, relevant
questions were incorporated into a wider ethically-approved survey
designed to capture multiple datasets from respondents. The ques-
tionnaire was approved by the NRES Committee East Midlands-
Derby 1 Research Ethics Committee; distributed by post using the
Imperial College London HHTIC London Clinical Service databases
(2001 to 2012); during attendance at the HHT clinics; and advertised
by the HHT Foundation International. The basic study design has
been reported previously [6,34–36]. Exact wording of relevant ques-
tions is provided in the e-component (Survey Extracts). To facilitate
maximal completion, for each set of questions, respondents were
directed to one of several alternate “loops”, each containing the ap-
propriate questions according to their answers to key preceding
questions.
Respondents' answers to HHT-related questions permitted indepen-
dent assignment of their HHT-status based on the Curaçao criteria [37]that were applied through the algorithm in reference [34], and this
was performed blinded to all other data. One of the ﬁnal survey ques-
tions asked respondents to provide their date of birth: this was used
as a ﬁrst check of standard of completion (see below). For each parent
and grandparent, the survey stated the gender and relationship to the
respondent, and respondents were asked to report using drop down
boxes: the ﬁnal age of the individual (at death or 2012 censor); if HHT
was known to be present; whether they had a “heart attack (myocardial
infarction)”; and age at ﬁrst “heart attack (myocardial infarction)”. Free
text options were provided allowing additional details to be reported.
The survey was open from April 2012 to April 2013. Preliminary
analyses of the cardiac phenotypes were performed by students during
2013, and included the assignment of HHT phenotypes used in the cur-
rent study. To extend for theﬁnal analyses reported in the currentman-
uscript, all data from the survey were downloaded from SurveyMonkey
in 2015.
2.2. Data analyses and statistics
2.2.1. Proband (respondent) analyses
Personal phenotypes reported by survey participants were
downloaded in six anonymized Excel sheets. The data were trans-
formed to numeric indices using Microsoft Excel “replace” commands,
and copied to a single Excel sheet that did not include the ﬁnal HHT
diagnostic assignments. Following data transformation, an HHT diag-
nostic column (yes (1), no (0), unknown (.)) was added in using the
Excel “vlookup” command to generate “vlookupHHT”, and data were
uploaded to a STATA datasheet. Further data analyses and statistical
evaluations were performed using STATA IC v11 (Statacorp, Texas).
New variables were generated and populated automatically in
STATA, particularly “ageknown” (where date of birth had been pro-
vided, required for study inclusion); “smokernonpassive” (counting
passive smokers as 0); “txgraded” where blood transfusion history
was weighted on a scale of 0–5 for never, once, 2–4, 5–10, 10–50,
and greater than 50 transfusions; “gradedNB” where maximum fre-
quency of nosebleeds (NB) was assigned on a scale of 0–5 for
never, b5 in life, once a year, once a month, once a week, and once
a day; arrhythmiaany (either arrhythmia/tachycardia or atrial ﬁbril-
lation); and miall (to capture the Mi phenotypes reported in differ-
ent columns). The original and ﬁnal datasheets will be supplied
upon publication to facilitate further analyses by other groups.
Two group comparisons were performed using Mann Whitney,
three ormore groups by KruskalWallis with p-values for twoway com-
parisons calculated by post-test Dunn's correction. HHT cardiac pheno-
types and pulmonary hypertension were examined by logistic
regression “if vlookuphht==1 & age known==1”. Following univar-
iate logistic regression, multivariate analyses initially examined simul-
taneously age, gender, graded nosebleeds, pulmonary AVMs, cerebral
AVMs, liver AVMs, gastrointestinal HHT, transfused (yes/no), iv iron
(yes/no), iron tablets ever (yes/no), still anemic on iron tablets, smoker
(yes/no, and not passive), and alcohol graded; arthritis; asthma; high
blood pressure; COPD/emphysema; deep vein thrombosis /pulmonary
emboli (venous thromboemboli); diabetes; inﬂammatory bowel dis-
ease; liver problems (not related to HHT); kidney problems; osteoporo-
sis; polyps in colon; pulmonary hypertension; sleep apnea; stroke or
transient ischemic attack; and varicose veins. Step wise removal of the
least signiﬁcant variable was used to generate the preﬁnal model. Phe-
notypes were then added back individually to see if they increased the
strength of the model. The ﬁnal models reported are the models
explaining the greatest proportion of the variance including both HHT
phenotypes, and nonHHT disease states that made independent contri-
butions to themodel, once adjusted for all other variables in themodel.
2.2.2. Familial analyses
The study design also permitted capturing of a more restricted
dataset on respondents' relatives. Familial data within the six
Table 1
HHT demographics of the 1025 individuals.
HHT variable N Count Percent
Nosebleeds (epistaxis)
Any nosebleeds 1025 942 91.9
At least weekly 1025 804 78.4
At least daily 1025 452 44.1
AVMs and other vascular lesionsa
Pulmonary AVMs 1025 544 53.1
Hepatic AVMs 1025 194 18.9
Gastrointestinal HHT 1024 97 9.47
Cerebral AVMs 1025 92 8.98
Genitourinary AVMs 1024 10 0.98
Pancreatic AVMs 1025 7 0.68
Splenic AVMs 1025 5 0.49
HHT treatments received for
Epistaxis 1025 479 46.7
Skin telangiectasia 1025 242 23.6
Gastrointestinal HHT 1025 132 12.9
Pulmonary AVMs 1025 352 34.3
Cerebral AVMs 1025 57 5.56
Hepatic AVMs 1025 25 2.44
Blood transfusionb 1025 374 36.5
Intravenous iron 1025 256 25.0
Oral iron tablets 1025 770 75.1
a Additionally, 3 (0.29%) reported uterine AVMs, 3 (0.29%) spinal, 2 (0.20%) ocular, 2
(0.20%) cardiac/mediastinal, 1 breast, 1 bone and 1 respondent reported gall bladder
AVMs.
b 31/1025 (3.0%) reported blood transfusions on N50 occasions (Grade 5); 69 (6.7%) on
10–50 occasions (Grade 4), 61 (6.0%) on 5–10 occasions (Grade 3); 102 (10.0%) on 2–4 oc-
casions (Grade 2) and 111 (10.8%) had received a single blood transfusion of 2–4 units of
blood (Grade 1).
Table 2
Reported cardiac phenotypes.
Number Percentage
Angina or any heart problem 1025 164 16.00
Any arrhythmia/tachycardiaa 1025 113 11.02
Atrial ﬁbrillation 1025 44 4.29
Valve problems 1025 48 4.68
Anginaa 1025 36 3.51
Heart failurea 1025 26 2.54
Heart attack (myocardial infarct)a 1025 23 2.24
Electrophysiological studies 1025 21 2.05
Pacemaker 1025 12 1.17
Automatic deﬁbrillator 1025 8 0.78
Coronary angioplasty 1025 23 2.25
Open heart surgery 1025 18 1.77
a These phenotypes are examined further below.
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Blinded to all other data, HHT diagnostic assignments were per-
formed for the parents and grandparents of all respondents meeting
the HHT diagnostic criteria, even if the proband had not provided
their personal date of birth correctly. Assignments utilized the auto-
somal dominant pattern of inheritance observed in all HHT families
to date, and an HHT prevalence of ~1 in 5000 based on reported
data for the general population [23,25,38,39].
HHT diagnostic assignments were performed using approaches uti-
lized previously [27,31,34] to capture data from individuals who may
not have survived to the point of data capture; to provide a nonHHT
control group subject to the samemethodology; and for this rare condi-
tion, to increase the overall cases assessable through the study: where
the presence of HHT was not reported for either parent of an HHT-
affected respondent, both parents were classiﬁed as unknowns (.) and
excluded from all subsequent analyses. If one parent of an HHT-
affected respondentwas reported to haveHHT, this parentwas assigned
as HHT-affected, and the other parent as HHT-unaffected. These as-
signments were repeated for the parents of HHT-affected fathers of
respondents, and then HHT-affected mothers of respondents, thus
identifying a proportion of the HHT-affected grandparents of the re-
spondents. Overall, 417 fathers, 482 mothers, 457 grandfathers, and
621 grandmothers were reported to have HHT.
For the HHT-unaffected parent of a respondent, both of their parents
(i.e. the respondent's grandparents on that side of the pedigree) were
designated as HHT-unaffected. It was accepted that there could be up
to a 1 in 5000 chance that one of these individuals designated as HHT-
unaffected would by chance, and unknown to their relatives, also have
HHT, but this risk was considered acceptable and unlikely to materially
inﬂuence the study analyses. Conﬁdently-assigned nonHHT branches of
the families provided 582 fathers, 457 mothers, 1069 grandfathers, and
903 grandmothers. The strict requirements required for HHT exclusion
meant that over 30% of the predicted HHT-unaffected parents and
grandparents were assigned “unknown” status and excluded from the
analyses, prior to review of cardiac data.
Where parental or grandparental ages were not provided, ageswere
classiﬁed as unknown (.). As for individuals of unknown HHT status, if
age was unknown (.), all data from that individual were excluded
from further analyses.
Where the age at myocardial infarction was unknown to the pro-
band, to avoid bias through exclusion, or augmentation of any potential
differences between HHT groups, the myocardial infarct events were
distributed evenly according to the combined distribution ofmyocardial
infarcts in the gender across the combined HHT-affected and HHT-
unaffected dataset. The age was not known for 111/320 (34.7%) of fe-
male myocardial infarctions, and 125/542 (23.1%) of male myocardial
infarctions. These events were assigned to teens, 20s, 30s, 40s, 50s,
60s, 70s, 80s, and 90s of the respective HHT or nonHHT gender group,
using the distribution of the 209 known age female myocardial infarc-
tions, and 417 known age male myocardial infarctions across both
HHT and nonHHT. Again, the original and ﬁnal datasheets will be sup-
plied upon publication to facilitate further analyses by other groups.
3. Results
3.1. General HHT population demographics
1025 survey respondents who provided their date of birth met the
criteria for HHT diagnosis. The median age was 55 years (interquartile
range 44–64 years), and 675 (65.9%) were female. As indicated in
Table 1, 942 (91.9%) reported nosebleeds, with 452 (44.1%) describing
at least daily nosebleeds; 544 (53.1%) reported pulmonary AVMs; 194
(18.9%) hepatic AVMs; 97 (9.5%) gastrointestinal HHT, and 92 (9.0%) ce-
rebral AVMs. High proportions had been treated for HHTmanifestations
including 479 (46.7%) for the nose; 352 (34.3%) for pulmonary AVMs;
and 132 (12.9%) for gastrointestinal HHT. Of the 1025 respondents,770 (75%) had used iron tablets for anemia, 256 (25.0%) had received
intravenous iron infusions, and 374 (36.5%) had received blood transfu-
sions including 161 (15.7%) who had been transfused on at least 5 dif-
ferent occasions.
In addition, 340/1025 (33.1%) were current or former smokers; 227
(22.2%) reported high blood pressure; 64 (6.2%) diabetes; 165 (16.1%)
asthma; 43 (4.2%) COPD or emphysema, with additional diseases re-
ported as listed in Supplementary Table 1.
Fifty-eight of the 1025 HHT-affected respondents (5.7%) reported
pulmonary hypertension, including 27 (13.9%) of the patients reporting
hepatic AVMs. Adjusted odds ratios (OR) derived from logistic regres-
sion analyses (Supplementary Table 2), indicated that pulmonary hy-
pertension was more common if participants reported hepatic AVMs
(OR 4.67 [95% conﬁdence intervals (CI) 2.63, 8.27]); COPD/emphysema
(OR 4.04 [95% CI 1.73, 9.32]); sleep apnea (OR 3.53 [95% CI 1.78, 6.98]);
DVT/PE (OR 2.80 [95% CI 1.21, 6.45]); and/or use of iron tablets for ane-
mia (OR2.37 [95% CI 0.98; 5.70]). The surveymethodology did not allow
the speciﬁc capture of the pulmonary arterial hypertension phenotype
that is known to cause some cases of pulmonary hypertension in HHT.
Otherwise, theﬁnalmodel reﬂected the diverse pathophysiological con-
tributors to pulmonary hypertension in HHT, for which earlier
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nous hypertension” are most helpful [40,41].3.2. Cardiac-related phenotypes
Angina or heart problems were reported by 164/1025 (16.0%) of
the study population and are summarized in Table 2. The most com-
monly reported phenotype was an arrhythmia (reported by 113
(11.0%)), with 44 (4.3%) speciﬁcally reporting atrial ﬁbrillation. Val-
vular heart disease, angina, cardiac failure, andmyocardial infarction
were reported by 2–5% of the population (Table 2). Twenty-three
(2.2%) had required coronary angioplasty. Eighteen (1.7%) reported
previous open heart surgery, but this reduced to only four (0.04%)
when participants reporting valve problems were excluded. Three
respondents had survived cardiopulmonary resuscitation, and four
(0.039%) had survived thrombolysis.
Cardiac phenotypes were expected to be more common in pa-
tients with additional disease states both due to causality, and due
to ascertainment bias. This was used to validate the data using age
and gender adjusted logistic regression. Univariate analyses are pro-
vided in Supplementary Table 3. Brieﬂy, arrhythmias were more re-
ported 2.5–3.5-fold more frequently if there was coexistent asthma
or an inﬂammatory condition (arthritis; inﬂammatory bowel dis-
ease); angina was 2.7-fold more common if co-existing arthritis
was reported; cardiac failure was 4.4-fold more common with co-
existing sleep apnea; and myocardial infarction was 6.6-fold more
common if previous venous thromboemboli (DVT/PE) were reported
(all p-values ≤0.002). The strongest associations were with pulmo-
nary hypertension with respective odds ratios of 6.22 [95% CI 3.51,
11.0] for arrhythmias; 4.25 [95% CI 1.76, 10.24] for angina; 8.46
[95% CI 3.48, 20.54] for cardiac failure and 6.18 [95% CI 2.07, 18.49]
for myocardial infarction. Given the known causative role of pulmo-
nary hypertension in the generation of these cardiac phenotypes,
subsequent HHT-speciﬁc evaluations were performed with and
without the 58 patients with known pulmonary hypertension.Table 3
Logistic regression of cardiac phenotypes.
Adjusted odds ratio
(95% CI)
Standard
error
z
test
p
value
A) Arrhythmia
Blood transfusion (graded) 1.32 (1.35, 3.36) 0.50 3.23 0.001
Intravenous iron 1.82 (1.14, 2.88) 0.43 2.53 0.011
Pulmonary hypertension⁎ 4.77 (2.61, 8.72) 1.47 5.08 b0.001
Asthma 2.23 (1.39, 3.6) 0.54 3.30 0.001
Inﬂammatory bowel disease 3.51 (1.57, 7.80) 1.43 3.30 0.002
Arthritis 1.88 (1.20, 2.94) 0.43 2.78 0.006
B) Angina
Blood transfusion 4.23 (2.00, 8.98) 1.62 3.76 b0.001
Pulmonary hypertension 3.17 (1.28, 7.87) 1.47 2.49 0.013
Arthritis 2.22 (1.10, 4.50) 0.80 2.23 0.025
NonHHT liver problems 3.74 (1.02, 13.72) 2.47 1.99 0.047
C) Cardiac failure
Blood transfusion 9.57 (2.75, 33.3) 6.09 3.55 b0.001
Pulmonary hypertension⁎⁎ 6.12 (2.43, 15.5) 2.90 3.83 b0.001
Sleep apnea 3.97 (1.59, 9.88) 1.84 2.96 0.003
Age 1.04 (1.01, 1.09) 0.021 2.14 0.032
The ﬁnal models in 1025 patients presenting all variables making a signiﬁcant contribu-
tion, once adjusted for thepresence of other variables in themodel,withHHT-relatedphe-
notypes (in bold) listed ﬁrst. Variables are otherwise ranked by p-value magnitude.
A) Arrhythmia: pseudo r2 for ﬁnal model 0.14, p b 0.0001. B) Angina, pseudo r2 for ﬁnal
model 0.11, p b 0.0001. C) Cardiac failure: pseudo r2 for ﬁnal model 0.25, p b 0.0001.
Note that for arrhythmias, the model strength was increased by using the graded transfu-
sion variable, whereas for angina and heart failure, use of the graded transfusion variable
reduced the overall pseudo r2 for the model. Higher order variables were not signiﬁcant.
⁎ If replaced by hepatic AVMs, OR 1.74, p = 0.023, with overall model pseudo r2 0.11,
p b 0.0001.
⁎⁎ If replaced by hepatic AVMs: OR 1.74, p = 0.023, with overall model pseudo r2 0.22,
p b 0.0001.3.3. Arrhythmias, angina and cardiac failure associated with blood
transfusions, intravenous iron and hepatic AVMs
To explore potential HHT-related contributions to the cardiac
phenotypes, multivariate logistic regression was ﬁrst performed
using arrhythmias, angina, and cardiac failure in turn as the outcome
(dependent) variable. There were similarities in the three ﬁnal
models which are listed in Table 3 to facilitate comparisons.
For arrhythmias, the strongest HHT predictors in the presence and
absence of the pulmonary hypertension patients were the need for
blood transfusions and intravenous iron (Table 3A). These associations
were also evident once adjusted for the presence of arthritis, inﬂamma-
tory bowel disease, asthma and pulmonary hypertension (Table 3A). A
history of any blood transfusion doubled the reported rate of arrhyth-
mias (OR 2.13 [95% CI 1.35, 3.36], p = 0.001), but a stronger model
(Table 3A) was obtained using the graded transfusional variable
which gave additional weighting to patients receiving more transfu-
sions. For each point on the 6 point scale, arrhythmia reports increased
1.33-fold (OR 1.32 [95% CI 1.15, 1.53], p b 0.0001), thus patients receiv-
ing N50 transfusions were 7.4-fold more likely to report arrhythmias,
once adjusted for the presence of all other variables in the model. He-
patic AVMs could partially replace pulmonary hypertension, but this
marginally reduced the overall strength of the model.
Blood transfusionwas the only HHT variable to be associatedwith
angina. The odds ratio increased when the 58 patients with pulmo-
nary hypertension were excluded. An association with any blood
transfusion persisted after adjustment for the ‘nonHHT’ associated
conditions (i.e. angina, arthritis, nonHHT liver problems, and pulmo-
nary hypertension, Table 3B).
High output cardiac failure is a recognized complication of hepat-
ic [20] and other systemic AVMs [3,4,8]. In the ﬁnal model, cardiac
failure was strongly associated with blood transfusion, increased
with age, and there was also an association with hepatic AVMs al-
though this was dependent on inclusion of the subgroup of 58 with
pulmonary hypertension, and not evident when adjusted for pulmo-
nary hypertension which provided a marginally stronger model
(Table 3C). Blood transfusion, age and pulmonary hypertension (or
hepatic AVMs) remained associated with cardiac failure after adjust-
ment for sleep apnea (Table 3C).
3.4. Unusual associations with myocardial infarction
23 HHT patients reported myocardial infarctions, with their ﬁrst
events occurring from 27 to 82 years of age (median 52 years). In
univariate analyses, compared to respondents without myocardial
infarcts, they were more likely to be smokers, or to report DVT/PE,
stroke/ministroke (TIA), or pulmonary hypertension (Supplementa-
ry Table 4, p values all b0.005). In univariate analyses, respondents
reporting myocardial infarcts were also more likely to require
blood transfusions (p = 0.01); have pulmonary AVMs (p = 0.03);
more severe nosebleeds (p = 0.030); and/or need intravenous ironTable 4
Logistic regression of myocardial infarction.
Adjusted odds ratio
(95% CI)
Standard error z test p value
Myocardial infarction
DVT/PE 3.77(1.3, 10.9) 2.04 2.45 0.014
Pulmonary hypertension 3.60 (1.23, 10.5) 1.97 2.34 0.019
Age 1.04 (1.002, 1.07) 0.018 2.06 0.039
Theﬁnalmodel in 1025 patients presenting all variablesmaking a signiﬁcant contribution,
once adjusted for the presence of other variables in the model. Variables are ranked by p-
value magnitude. Pseudo r2 for ﬁnal model 0.13, p b 0.0001. Note that there are no HHT-
related phenotypes listed — adding back individually to the above model provide the fol-
lowing odds ratios and p values: smoking OR 1.98, p = 0.11; stroke/ministroke (TIA) OR
2.1, p = 1.49; blood transfusion, OR 0.98, p = 0.96; pulmonary AVMs OR 1.40, p =
0.45; nosebleeds (graded) OR= 1.03, p = 0.84; and intravenous iron; OR 0.98, p = 0.96.
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type were relatively modest however, and did not emerge in multiple
regressionwhen therewere also no associationswith smoking once ad-
justed for the presence of DVT/PE, pulmonary hypertension, and age
(Table 4). Unlike the other cardiac phenotypes, hepatic AVMs could
not replace pulmonary hypertension in themodel: only one respondent
who reported a myocardial infarction also reported hepatic AVMs.
3.5. Low rates of myocardial infarctions and abnormal coronary
angiograms in HHT
Notwithstanding the unusual associations with myocardial infarc-
tion, the relatively low reported prevalence (23/1024, 2.2%) [42] for
such an apparently ‘at risk’ population was also striking. Furthermore
76 of the 1025 survey respondents (7.4%) had undergone angiography,
and in at least 35/76 (46%) of these cases, the angiogram was reported
to be normal. However, patients who had already died due to amyocar-
dial infarctionwould be unable to complete the survey, therefore poten-
tially confounding the data.
To examine further in a less confounded manner, events were com-
pared including respondents' parents and grandparents for whom HHT
could be assigned or excluded with conﬁdence. Overall, the HHT pro-
bands, and their relatives provided data for 1043 males and 1415 fe-
males with HHT; 1036 males and 992 females without HHT. Of these
4486 individuals, 532 (11.9%) were reported to have had a myocardial
infarction/heart attack. There was no obvious difference in ages at ﬁrst
myocardial infarction according to the presence or absence of HHT
(Fig. 1A). However, in crude analyses,myocardial infarctswere reported
less frequently for individuals with HHT (Fig. 1B), and this reduction
persisted following age-adjustments. Survival analyses indicated that
for males with HHT, the risk of a myocardial infarct was lower at all
ages (p = 0.001, Fig. 1C). The risk of myocardial infarcts also tendedFig. 1.Myocardial infarction rates in relatives with and without HHT A) Age distribution for ﬁr
symbols and lines), orwithout HHT (open symbols and dashed lines). B) Crude prevalence ofM
values calculated by Dunn's tests after Kruskal Wallis evaluation of all 4 groups combined. C)
without HHT.to be lower for females with HHT (p = 0.049, Fig. 1D), particularly
after the age of 60 years.
4. Discussion
We have shown using survey based methodology that the most
common cardiac phenotype in HHT is arrhythmias; that HHT patients
with anemia requiring blood transfusions and/or intravenous iron are
more likely to have arrhythmias, angina and heart failure, but that over-
all, the rate of myocardial infarction appears to be reduced in people
with HHT, and is related to indices of venous thromboemboli and not
typical risk factors for ischemic heart disease.
Study strengths are that data on diverse phenotypes were cap-
tured on a large population with this rare condition, and validated
by conﬁrming logical deductions regarding which patients should
be more likely to report cardiac phenotypes. Age was part of only
two models, and gender was not part of any cardiac phenotypic
model. This does not imply that cardiac phenotypes did not increase
with age or gender (note Fig. 1), instead that any age or gender-
related phenotypes were better explained by other components of
the relevant models. An additional strength was the inclusion of rel-
atively rigorously assessed respondents' relatives to reduce potential
bias from deceased individuals being unable to respond.
The main study weakness is that it is survey based. Although every
effortwasmade to eliminate potential bias duringdata analysis,we can-
not exclude bias in terms of study participation, or participant recall.
Furthermore, phenotypic data were particularly limited on the relatives
of respondentswhere itwould have been valuable to know the distribu-
tion of other phenotypes associated with myocardial infarction in this
HHT series (venous thromboemboli, pulmonary hypertension) and
wider population risk factors such as smoking, diabetes, hypercholes-
terolemia, and hypertension [42].st myocardial infarction (MI) in males (diamonds), and females (circles), with HHT (solid
Is in 1043males and 1415 females with HHT; 1036males and 992 femaleswithout HHT. p
Survival curves for males with and without HHT. D) Survival curves for females with and
184 C.L. Shovlin et al. / International Journal of Cardiology 215 (2016) 179–185While exact statistical comparisons are not feasible, compared to
general population ﬁgures, [42,43] the 1025 respondents with HHT
with median age of 55 years, appeared to report broadly comparable
rates of angina (3.5% versus 3.3% [42]), higher rates of tachycardia/ar-
rhythmias (11% versus 3–4% [42]) but potentially lower rates of heart
failure [42,43] and myocardial infarction [42]. The reduced rate of myo-
cardial infarction is difﬁcult to assign to methodological bias since all
relatives' data were captured in an identical manner, and is particularly
challenging to explain. Somewhat unlikely possibilities are that HHT pa-
tients prone to myocardial infarction had these before the age of repro-
duction and did not have children, or that those who would have gone
on to have myocardial infarctions had died earlier from other diseases.
As for cancer [34], we prefer an alternate hypothesis, particularly in
view of the high proportion of normal coronary angiograms, that the
rate of coronary artery disease may be reduced in people with HHT.
This will need to be subject of future studies.
The association data suggest two separate sets of cardiac phenotypes
in HHT. Myocardial infarctions demonstrated strong associations with
venous thromboemboli (Table 4), potentially in keeping with paradox-
ical embolic processes as proposed elsewhere [12]. In a separate HHT
observational study, myocardial infarctions and paradoxical embolic
strokes displayed common risk factors [13].
Angina, heart failure and arrhythmias shared a different set of as-
sociations (Table 3). Pulmonary hypertension and hepatic AVMs
were relatively interchangeable in these cardiac phenotype models,
and likely reﬂect that the most signiﬁcant associations with hepatic
AVMs are through patients with the most severe left-to-right shunts,
higher cardiac indices, and more severe non-cardiac pulmonary ve-
nous hypertension [3,4,8,40,41]. For angina and heart failure,
where medical management includes recommendations to optimize
oxygen delivery, associations with anemia treatments in acute
(blood transfusions) and subacute (intravenous iron) settings are
not particularly surprising. This seems less applicable to arrhythmia
management, but cannot be excluded. Furthermore, for, arrhyth-
mias, a stronger model was obtained with graded transfusions, sug-
gesting that the highest risk was with a state requiring recurrent
transfusions as opposed to individual transfusions. Two alternate in-
terpretations are proposed. First, the association data would also be
compatible with these cardiac phenotypes being more prevalent in
more anemic patients with higher cardiac outputs due to AVMs: ar-
rhythmias and angina may then reﬂect the adrenergic stimuli re-
quired to maintain high cardiac outputs required in the face of
anemia and AVMs [3,7,44], with age-related components reﬂecting
lesser ability of the aging heart, and particularly the aging sinoatrial
node, to sustain the increased cardiac output required. We cannot
rule out an alternate, and not mutually exclusive possibility that
the anemia treatments may aggravate the cardiac phenotypes. This
is important to consider in the light of two sets of recent data: ﬁrst
5–7% of HHT patients report immediate exacerbation of nosebleeds
by iron treatments and transfusions [45], and multiple studies em-
phasize the rapid increases in serum iron after iron treatments
[45–52]. Secondly, an RNASeq-based study demonstrates that
10 μM iron generates rapid molecular and cellular changes in prima-
ry human endothelial cells, compatible with activation of DNA dam-
age response pathways [53] — the concentration required is similar
to clinical concentrations of nontransferrin bound iron (NTBI) after
iron treatments [47–52], and much lower than those used in previ-
ous studies of endothelial iron toxicity [54,55]. It may be relevant
that there was a greater disparity in myocardial infarction rates be-
tween HHT affected and unaffected grandparents than parents, and
further study is required.
In summary, arrhythmias are the most common cardiac phenotype
in HHT. They have not previously been the focus in HHT, other than
discussions regarding the difﬁculties involved in anticoagulation for
cardioversion [36,56]. The arrhythmia, angina, and heart failure data
emphasize the need to better understand the management of irondeﬁciency anemia and high output states in the HHT population. Sur-
prisingly, despite major circulatory challenges, and additional risks of
paradoxical embolicmyocardial infarctions [9,12,13],myocardial infarc-
tion rates appear to be reduced in people with HHT.
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